CN102740894B - 用于治疗缺血组织的sdf-1递送 - Google Patents

用于治疗缺血组织的sdf-1递送 Download PDF

Info

Publication number
CN102740894B
CN102740894B CN201080043895.7A CN201080043895A CN102740894B CN 102740894 B CN102740894 B CN 102740894B CN 201080043895 A CN201080043895 A CN 201080043895A CN 102740894 B CN102740894 B CN 102740894B
Authority
CN
China
Prior art keywords
sdf
plasmid
ischemic
injection
peri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080043895.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102740894A (zh
Inventor
M·S·佩恩
R·阿拉斯
J·帕斯托
T·R·米勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of CN102740894A publication Critical patent/CN102740894A/zh
Application granted granted Critical
Publication of CN102740894B publication Critical patent/CN102740894B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201080043895.7A 2009-08-28 2010-08-30 用于治疗缺血组织的sdf-1递送 Active CN102740894B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23777509P 2009-08-28 2009-08-28
US61/237,775 2009-08-28
US33421610P 2010-05-13 2010-05-13
US61/334,216 2010-05-13
PCT/US2010/047175 WO2011026041A2 (en) 2009-08-28 2010-08-30 Sdf-1 delivery for treating ischemic tissue

Publications (2)

Publication Number Publication Date
CN102740894A CN102740894A (zh) 2012-10-17
CN102740894B true CN102740894B (zh) 2015-07-15

Family

ID=43628693

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080043895.7A Active CN102740894B (zh) 2009-08-28 2010-08-30 用于治疗缺血组织的sdf-1递送

Country Status (9)

Country Link
US (5) US20120283315A1 (cg-RX-API-DMAC7.html)
EP (1) EP2473196B1 (cg-RX-API-DMAC7.html)
JP (1) JP5856059B2 (cg-RX-API-DMAC7.html)
CN (1) CN102740894B (cg-RX-API-DMAC7.html)
AU (1) AU2010286511B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012004395B8 (cg-RX-API-DMAC7.html)
CA (1) CA2772610C (cg-RX-API-DMAC7.html)
MX (1) MX357779B (cg-RX-API-DMAC7.html)
WO (1) WO2011026041A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140170116A9 (en) 2002-08-22 2014-06-19 Marc S. Penn Method of treating ischemic disorders
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
AU2010286511B2 (en) 2009-08-28 2016-05-26 Juventas Therapeutics, Inc. SDF-1 delivery for treating ischemic tissue
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
JP5921558B2 (ja) * 2010-10-14 2016-05-24 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 心臓人工多能性幹細胞ならびに心筋の修復および再生に使用する方法
US20130136729A1 (en) * 2011-11-11 2013-05-30 University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group Compositions and methods for targeting and treating diseases and injuries using adeno-associated virus vectors
JP6461085B2 (ja) * 2013-03-15 2019-01-30 ザ クリーブランド クリニック ファウンデーション 虚血性組織を治療するためのｓｄｆ−１送達
JP2016516070A (ja) * 2013-03-15 2016-06-02 ザ クリーブランド クリニック ファウンデーション 心筋梗塞の処置のためのｓｄｆ−１の逆行性送達
WO2014145236A2 (en) * 2013-03-15 2014-09-18 Juventas Therapeutics, Inc. The use of sdf-1 to mitigate scar formation
US10166044B1 (en) 2013-05-31 2019-01-01 Freshwater Bay Industries, Llc Apparatus for repositioning the vagina, cervix, uterus and pelvic floor and method to secure same
US20160278810A1 (en) 2013-05-31 2016-09-29 Mark Edmund Richey Vaginal surgical apparatus
WO2015168145A1 (en) * 2014-04-28 2015-11-05 Penn Marc S Sdf-1 delivery for treating advanced ischemic cardiomyopathy
WO2015171417A1 (en) 2014-05-08 2015-11-12 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
ES3048233T3 (en) 2014-12-23 2025-12-09 Ilya Pharma Ab Methods for wound healing
RU2758489C2 (ru) 2015-11-11 2021-10-28 Пресиджен, Инк. Композиции и способы для экспрессии нескольких биологически активных полипептидов с одного вектора для лечения заболеваний сердца и других патологий
CA3055761A1 (en) * 2017-03-30 2018-10-04 Wake Forest University Health Sciences Methods of treatment for kidney disease
US11583571B2 (en) 2017-05-13 2023-02-21 The Johns Hopkins University Stromal derived factor 1 and its use in the prevention and treatment of erectile dysfunction
WO2019032930A1 (en) 2017-08-11 2019-02-14 Wake Forest University Health Sciences USE OF CXCL12 FOR THERAPY AFTER SURGERY OF THE PROSTATE
EP3781182A4 (en) * 2018-04-18 2021-11-17 Summa Health COMPOSITIONS AND METHODS OF TREATMENT OF ISCHEMIA AND CARDIOMYOPATHIA

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US20020031803A1 (en) * 1997-06-20 2002-03-14 Cooper Mark J. Expression system for production of therapeutic proteins
US5602301A (en) 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
CA2188575A1 (en) 1995-02-28 1996-09-06 H. Kirk Hammond Gene transfer-mediated angiogenesis therapy
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5980887A (en) 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
NZ336838A (en) * 1997-01-29 2002-04-26 Cornell Res Foundation Inc A method of enhancing the level of perfusion of blood to a target tissue by administering an adenoviral vector encoded with an angiogenic peptide within 0.5-15 cm3 of the tissue
EP0998486B2 (en) 1997-06-13 2012-02-01 Genentech, Inc. Protein recovery by chromatography followed by filtration upon a charged layer
MXPA00003885A (es) 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
JP2002502608A (ja) 1998-02-06 2002-01-29 コラテラル・セラピューティックス・インコーポレイテッド 血管新生促進因子である血管内皮細胞成長因子：ｖｅｇｆの変異体
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
CA2322559C (en) 1998-03-09 2012-07-17 St. Elizabeth's Medical Center Compositions and methods for modulating vascularization
WO1999050461A1 (en) 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
US20020107196A1 (en) 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
IL125532A0 (en) 1998-07-27 1999-03-12 Yeda Res & Dev Hematopoietic cell composition for use in transplantation
AU5241099A (en) 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
WO2000015285A1 (en) * 1998-09-14 2000-03-23 Mirus Corporation A process for delivering nucleic acids to cardiac tissue
DE19844479C1 (de) 1998-09-28 2000-04-13 Siemens Ag Integrierter Speicher mit einem differentiellen Leseverstärker
US7399751B2 (en) 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
EP1013770A1 (en) * 1998-12-23 2000-06-28 Université Louis Pasteur de Strasbourg Non-viral transfection vector
DE19900743A1 (de) * 1999-01-12 2000-07-13 Aventis Pharma Gmbh Neue komplexbildende Proteine
US6333194B1 (en) 1999-01-19 2001-12-25 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
EP1154780A2 (en) 1999-02-26 2001-11-21 University Of Pittsburgh Of The Commonwealth System Of Higher Education Bone marrow transplantation for hepatic regeneration and repair
US20050153451A1 (en) * 1999-02-26 2005-07-14 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
EP1041148A1 (en) 1999-04-02 2000-10-04 Mogen International N.V. Pathogen inducible promoter
US6448054B1 (en) 1999-04-08 2002-09-10 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
US7125856B1 (en) 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
AU4801501A (en) * 2000-05-26 2001-11-29 Transgene S.A. Complex for transferring an anionic substance of interest into a cell
WO2001094420A1 (en) 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
AU2001284695A1 (en) 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
CA2386103A1 (en) * 2000-08-04 2002-02-14 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
US7402567B2 (en) 2000-10-27 2008-07-22 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
WO2002036078A2 (en) 2000-11-05 2002-05-10 University Of Florida Targeting pluripotent stem cells to tissues
US7405076B2 (en) 2000-11-14 2008-07-29 Universite Libre De Bruxelles Generation and use of dendritic cells
AU2002225756A1 (en) 2000-12-01 2002-06-11 Schering Corporation Uses of mammalian genes and related reagents
AR027161A1 (es) * 2001-05-15 2003-03-19 Bio Sidus S A Metodo para inducir la proliferacion neovascular y regeneracion tisular
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
WO2003014336A1 (en) 2001-08-07 2003-02-20 Kirin Beer Kabushiki Kaisha Process for preparing hematopoietic stem cells
ATE541921T1 (de) 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
US7402724B2 (en) 2002-01-04 2008-07-22 Mayo Foundation For Medical Education And Research Longevity and PAPP-A
AU2002226683A1 (en) 2002-01-17 2003-07-30 Cardio Incorporated Complex therapy for tissue regeneration
FR2843697B1 (fr) * 2002-08-26 2005-12-09 Sod Conseils Rech Applic L'heterocarpine, une proteine d'origine vegetale aux proprietes anticancereuses
US7396537B1 (en) 2002-02-28 2008-07-08 The Trustees Of The University Of Pennsylvania Cell delivery patch for myocardial tissue engineering
US7282222B2 (en) 2002-03-15 2007-10-16 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for directing cells to target organs
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20040037811A1 (en) * 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
US20050271639A1 (en) 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US20140170116A9 (en) 2002-08-22 2014-06-19 Marc S. Penn Method of treating ischemic disorders
US20040161412A1 (en) * 2002-08-22 2004-08-19 The Cleveland Clinic Foundation Cell-based VEGF delivery
JP2004099471A (ja) 2002-09-05 2004-04-02 Cardio Corp 心筋梗塞および心不全の治療薬
AU2003300332A1 (en) 2002-10-08 2004-05-04 American National Red Cross Method for enriching adherent monocyte populations
WO2004044142A2 (en) 2002-11-05 2004-05-27 The Brigham And Women's Hospital, Inc. Mesenchymal stem cells and methods of use thereof
US20040258670A1 (en) 2002-12-05 2004-12-23 Case Western Reserve University Cell-based therapies for ischemia
US20070036756A1 (en) * 2003-02-19 2007-02-15 Dnavec Research, Inc. Method for treating ischemic diseases
AU2003902037A0 (en) 2003-04-24 2003-05-15 Mclachlan, Craig Method for tissue growth
US20050104072A1 (en) 2003-08-14 2005-05-19 Slater David B.Jr. Localized annealing of metal-silicon carbide ohmic contacts and devices so formed
US7396680B2 (en) 2003-10-31 2008-07-08 Cornell Research Foundation, Inc. Stem cell-specific promoters and their use
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
US8071364B2 (en) * 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
JP5269411B2 (ja) 2004-06-21 2013-08-21 ザ クリーブランド クリニック ファウンデーション 幹細胞をホーミングさせるためのｃｃｒリガンド
EP1803464A4 (en) 2004-09-17 2009-09-09 Cellgentech Inc TOPICAL PREPARATION FOR THE TREATMENT OF SKIN DISEASES
CA2581652C (en) * 2004-09-27 2013-10-29 Valentis, Inc. Formulations and methods for treatment of inflammatory diseases
US20060105950A1 (en) 2004-10-25 2006-05-18 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Morphogen compositions and use thereof to treat wounds
WO2006083394A2 (en) 2004-12-21 2006-08-10 Ethicon, Inc. Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US7951632B1 (en) 2005-01-26 2011-05-31 University Of Central Florida Optical device and method of making
GB2424312B (en) 2005-03-14 2010-03-03 Denso Corp Method of forming an ohmic contact in wide band semiconductor
EP2546865B1 (en) 2005-09-16 2023-12-06 Wolfspeed, Inc. Methods of processing semiconductor wafers having silicon carbide power devices thereon
US8664664B2 (en) 2006-01-10 2014-03-04 Cree, Inc. Silicon carbide dimpled substrate
US20070173471A1 (en) 2006-01-24 2007-07-26 Losordo Douglas W Morphogen compositions and methods of use thereof to treat heart disorders
US7405195B2 (en) 2006-03-27 2008-07-29 Natural Beauty Bio-Technology Limited Cosmetic compositions
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
AU2010286511B2 (en) 2009-08-28 2016-05-26 Juventas Therapeutics, Inc. SDF-1 delivery for treating ischemic tissue
WO2012037083A2 (en) 2010-09-15 2012-03-22 The Cleveland Clinic Foundation Compositions and method for promoting musculoskeletal repair
US20120068161A1 (en) 2010-09-16 2012-03-22 Lee Keon-Jae Method for forming graphene using laser beam, graphene semiconductor manufactured by the same, and graphene transistor having graphene semiconductor
JP5569376B2 (ja) 2010-12-07 2014-08-13 住友電気工業株式会社 半導体装置の製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction;Ming Zhang et al;《The FASEB Journal》;20071031;第21卷;第3197-3207页，标题和摘要 *

Also Published As

Publication number Publication date
WO2011026041A2 (en) 2011-03-03
US20140135383A1 (en) 2014-05-15
AU2010286511A1 (en) 2012-04-12
JP5856059B2 (ja) 2016-02-09
BR112012004395A2 (pt) 2016-11-16
US8513213B2 (en) 2013-08-20
US8513007B2 (en) 2013-08-20
US20130303597A1 (en) 2013-11-14
EP2473196A2 (en) 2012-07-11
CA2772610A1 (en) 2011-03-03
US9844581B2 (en) 2017-12-19
US20120283315A1 (en) 2012-11-08
CA2772610C (en) 2018-01-23
WO2011026041A9 (en) 2011-07-21
US20120289586A1 (en) 2012-11-15
CN102740894A (zh) 2012-10-17
MX2012002610A (es) 2012-08-23
BR112012004395B8 (pt) 2021-05-25
BR112012004395B1 (pt) 2021-01-12
MX357779B (es) 2018-07-24
US8883756B2 (en) 2014-11-11
EP2473196A4 (en) 2015-01-07
JP2013503202A (ja) 2013-01-31
AU2010286511B2 (en) 2016-05-26
EP2473196B1 (en) 2017-05-31
US20120289585A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
CN102740894B (zh) 用于治疗缺血组织的sdf-1递送
Rincon et al. Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation
Turnbull et al. Myocardial delivery of lipidoid nanoparticle carrying modRNA induces rapid and transient expression
US20040161412A1 (en) Cell-based VEGF delivery
EP2142206A1 (en) Method of treating ischemic disorders
US8933048B2 (en) Methods of treating cardiomyopathy
US20110118333A1 (en) Use on Minicircle vectors for cardiac gene therapy
CN105264071B (zh) 用于治疗缺血组织的sdf-1递送
JP4652325B2 (ja) 虚血性疾患用の低酸素状態誘導可能ｖｅｇｆプラスミド
US20170049856A1 (en) Sdf-1 delivery for treating advanced ischemic cardiomyopathy
Cui et al. Enhancement of Angiogenesis by Ultrasound‐Targeted Microbubble Destruction Combined with Nuclear Localization Signaling Peptides in Canine Myocardial Infarction
WO2025240625A1 (en) Cbin1 therapy improves atrial electrical and functional remodeling, limiting atrial arrhythmias in failing hearts
WO2025226857A2 (en) Compositions and methods for treating hypoxia-related conditions
WO2015153357A1 (en) Compositions and methods for improving cardiac function
KR20230024268A (ko) 내피 세포 및 혈관 형성을 위한 전사 인자 etv2 유전자를 사용한 직접 생체 내 재프로그래밍

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant